Stanford Cardiovascular Institute (M.S., T.Q., M.P.F., J.C.W.).
Division of Cardiovascular Medicine, Department of Medicine (M.S., T.Q., J.C.W.), Stanford University School of Medicine, CA.
Circ Res. 2021 Mar 5;128(5):670-686. doi: 10.1161/CIRCRESAHA.120.318049. Epub 2021 Mar 4.
The developmental origin of vascular smooth muscle cells (VSMCs) has been increasingly recognized as a major determinant for regional susceptibility or resistance to vascular diseases. As a human material-based complement to animal models and human primary cultures, patient induced pluripotent stem cell iPSC-derived VSMCs have been leveraged to conduct basic research and develop therapeutic applications in vascular diseases. However, iPSC-VSMCs (induced pluripotent stem cell VSMCs) derived by most existing induction protocols are heterogeneous in developmental origins. In this review, we summarize signaling networks that govern in vivo cell fate decisions and in vitro derivation of distinct VSMC progenitors, as well as key regulators that terminally specify lineage-specific VSMCs. We then highlight the significance of leveraging patient-derived iPSC-VSMCs for vascular disease modeling, drug discovery, and vascular tissue engineering and discuss several obstacles that need to be circumvented to fully unleash the potential of induced pluripotent stem cells for precision vascular medicine.
血管平滑肌细胞(VSMCs)的发育起源越来越被认为是血管疾病易感性或抗性的主要决定因素。作为对动物模型和人原代培养的人类基于材料的补充,患者诱导多能干细胞(iPSC)衍生的 VSMCs 已被用于进行血管疾病的基础研究和开发治疗应用。然而,大多数现有诱导方案衍生的 iPSC-VSMCs(诱导多能干细胞 VSMCs)在发育起源上存在异质性。在这篇综述中,我们总结了调控体内细胞命运决定和体外不同 VSMC 祖细胞衍生的信号网络,以及终末特化谱系特异性 VSMCs 的关键调节因子。然后,我们强调了利用患者来源的 iPSC-VSMCs 进行血管疾病建模、药物发现和血管组织工程的重要性,并讨论了为充分发挥诱导多能干细胞在精准血管医学中的潜力而需要克服的几个障碍。